By Fineline Cube Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that its SHR-7590 injection has received clinical trial approval from China’s National Medical Products Administration (NMPA) for the treatment of ulcerative colitis and Crohn’s disease, advancing the company’s independently developed biologic into clinical testing in inflammatory bowel disease (IBD).
Regulatory Milestone
| Item | Detail |
|---|---|
| Company | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) |
| Agency | NMPA (China) |
| Approval Type | Clinical trial approval |
| Drug | SHR-7590 injection (therapeutic biologic) |
| Indications | Ulcerative colitis; Crohn’s disease |
| Approval Date | 13 Aug 2026 |
| Competitive Position | No drug targeting the same pathway approved globally to date |
Preclinical Profile – SHR-7590
- Molecule: A therapeutic biologic independently developed by Hengrui Pharma
- Anti-Inflammatory Activity: In animal models of inflammatory bowel disease (IBD), SHR-7590 demonstrated effective inhibition of inflammation
- Disease Improvement: Animal studies showed improvement in disease scores and alleviation of intestinal tissue pathology
- First-in-Pathway Opportunity: Currently, no drug targeting the same pathway has been approved for marketing globally, positioning SHR-7590 in a potentially first-in-class competitive landscape
Market Impact & Outlook
- Large Unmet Need: Ulcerative colitis and Crohn’s disease together constitute IBD, a chronic, relapsing condition with growing prevalence in China and substantial unmet need beyond existing biologics.
- Novel Pathway Differentiation: A mechanism with no globally approved incumbent offers Hengrui a differentiated entry point in a market long dominated by TNF, IL-12/23, and integrin inhibitors.
- Hengrui’s Biologics Push: The clearance extends Hengrui’s pipeline beyond oncology into immunology and inflammation, a strategic growth pillar for China’s largest pharmaceutical company.
- Next Steps: Trial design, dosing, and timelines for first-in-human dosing were not disclosed.
Forward‑Looking Statements
This brief contains forward-looking statements regarding the clinical development potential of SHR-7590. Actual results may differ due to risks including clinical progress, safety outcomes, and competitive dynamics in IBD biologics.-Fineline Info & Tech